Receptos to Hold First Quarter 2015 Results Conference Call
April 29 2015 - 8:00AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, will review financial results for the first
quarter ended March 31, 2015 on Tuesday, May 5, 2015 after the
markets close. The announcement will be followed by a live webcast
and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific
time).
Receptos management will host the call and webcast to discuss
financial results and recent business highlights. The live call may
be accessed by phone by calling (866) 757-6808 (domestic) or (760)
536-5211 (international), conference ID 27905354. The webcast can
be accessed live on the Investor Relations section of the Receptos
website at www.receptos.com and will be archived for 14 days
following the call. A replay of the call will be available by
phone by calling (855) 859-2056 or (404) 537-3406, conference ID
27905354.
About Receptos
Receptos is a biopharmaceutical company developing
therapeutic candidates for the treatment of immune and metabolic
diseases. The Company's lead program, ozanimod (formerly RPC1063),
is a sphingosine 1-phosphate 1 and 5 receptor small molecule
modulator in development for immune indications including relapsing
multiple sclerosis and inflammatory bowel disease. Patents
supporting RPC1063 were exclusively licensed to
Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046,
an anti-interleukin-13 (IL-13) antibody for eosinophilic
esophagitis, an immune-mediated orphan disease.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024